SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 221928.
  • 2
    Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 97180.
  • 3
    Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 15959.
  • 4
    Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 362332.
  • 5
    Wallace D. Current and emerging lupus treatments. Am J Manag Care 2001; 7: S4905.
  • 6
    Spronk PE, Horst G, van der Gun BT, Limburg PC, Kallenberg CG. Anti-dsDNA production coincides with concurrent B and T cell activation during development of active disease in systemic lupus erythematosus (SLE). Clin Exp Immunol 1996; 104: 44653.
  • 7
    Crispin JC, Tsokos GC. Novel molecular targets in the treatment of systemic lupus erythematosus. Autoimmun Rev 2008; 7: 25661.
  • 8
    Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358: 92939.
  • 9
    Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001; 166: 29136.
  • 10
    Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med 2005; 353: 111423.
  • 11
    Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 144: 86576.
  • 12
    Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 2009; 36: 73642.
  • 13
    Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 38391.
  • 14
    Bristol-Myers Squibb, sponsor. Abatacept in the treatment and prevention of active systemic lupus erythematosus (SLE) flares in combination with prednisone. ClinicalTrials.gov identifier:NCT00119678; 2009.
  • 15
    World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. URL: http://www.wma.net/en/30publications/10policies/b3/index.html.
  • 16
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 17
    Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 44758.
  • 18
    Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 2003; 42: 13729.
  • 19
    Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 3639.
  • 20
    Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. Pharmacoeconomics 1999; 15: 14155.
  • 21
    Wolfe F. Fatigue assessments in rheumatoid arthritis: comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 2004; 31: 1896902.
  • 22
    Spritzer KL, Hays RD. MOS Sleep Scale: a manual for use and scoring: version 1.0. Los Angeles: RAND Corporation; 2003.
  • 23
    Wells G, Li T, Maxwell L, MacLean R, Tugwell P. Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. J Rheumatol 2007; 34: 2809.
  • 24
    Radloff L. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385401.
  • 25
    Mehrotra DV, Railkar R. Minimum risk weights for comparing treatments in stratified binomial trials. Stat Med 2000; 19: 81125.
  • 26
    Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61: 116878.
  • 27
    National Institute of Allergy and Infectious Diseases, sponsor. Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis (ACCESS). ClinicalTrials.gov identifier: NCT00774852; 2009.
  • 28
    Bristol-Myers Squibb, sponsor. Efficacy and safety study of abatacept to treat lupus nephritis. ClinicalTrials.gov identifier: NCT00430677; 2009.